Dublin 4

• Early Sedation with Dexmedetomidine vs. Placebo in Older Ventilated Critically Ill Patients Recruiting
  2022-501157-36-00 6 2024-02-07 Critically ill patients who are dependent on high level medical care i
• Phase II Study of daTopotamab-derUXtecan (Dato-DXd; DS-1026a) in triple-negative brEast cancer patients with newly Diagnosed or prOgressing … Recruiting
  2024-518819-19-00 4 2023-05-23 triple negative breast cancer
• Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting
  2022-502425-18-00 5 2022-04-19 Adenocarcinoma of the prostate
• Single arm phase 2 trial of neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positiv … Recruiting
  2024-516582-36-00 10 2026-05-01 Early stage HER2-positive breast cancer
• AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) Recruiting
  2025-520466-22-00 5 2026-04-29 Advanced Platinum-resistant Epithelial Ovarian Cancer
• Visugromab in Cachexia International Trial Recruiting
  2025-523533-25-00 10 2026-03-26 Cancer-associated Cachexia
• A clinical study of opevesostat and standard hormone therapy in people with prostate cancer (MK-5684-004) Recruiting
  2023-504957-11-00 5 2026-03-24 Metastatic castration resistant prostate cancer
• Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Subjects With Primary Membranous Nephropathy Recruiting
  2025-521661-27-00 10 2025-12-19 Primary Membranous Nephropathy
• A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-033) Recruiting
  2024-517136-21-00 5 2025-12-05 Renal Cell Carcinoma
• A Phase 1/1b Study of IAM1363 in HER2 Cancers Recruiting
  2024-519188-17-00 1 2025-10-07 Relapsed/refractory malignancy with documented diagnosis of human epid
• Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen Recruiting
  2024-519875-24-00 5 2025-09-26 Carcinoid syndrome
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung … Recruiting
  2024-517780-24-00 5 2025-09-18 Lung Cancer
• Study of Daraxonrasib (RMC-6236) in Patients with RAS Mutated NSCLC Recruiting
  2024-518154-16-00 5 2025-08-27 non-small cell lung cancer
• A clinical study of sacituzumab tirumotecan and pembrolizumab in people with endometrial cancer (MK-2870-033) Recruiting
  2024-519331-42-00 5 2025-08-22 pMMR endometrial carcinoma
• EORTC 2022-MG: Treatment with tebentafusp or observation for patients with melanoma of the eye after surgery or radiation (ATOM Trial) Recruiting
  2023-510333-28-00 5 2025-08-20 Uveal Melanoma
• A clinical study of ifinatamab deruxtecan to treat metastatic prostate cancer (MK 2400 01A) Recruiting
  2024-516036-94-00 9 2025-08-12 Metastatic castrate resistant prostate cancer - mCRPC
• Phase 3 Study of I-DXd Versus Docetaxel in mCRPC Recruiting
  2024-517423-40-00 5 2025-06-23 Metastatic Castration-Resistant Prostate Cancer
• A Study to Compare the Efficacy and Safety of Vedolizumab With and Without Upadacitinib in Adults With Moderately to Severely Active Crohn's … Recruiting
  2023-509391-42-00 11 2025-06-02 Chron's Disease
• EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting
  2023-506817-23-01 5 2025-05-23 Metastatic hormone naïve prostate cancer (mHNPC)
• A clinical study of zilovertamab vedotin with R-CHP treatment in people with diffuse large B-cell lymphoma (MK-2140-011) Recruiting
  2024-515526-89-00 4 2025-05-16 Diffuse Large B-Cell Lymphoma (DLBCL)
• A study of elritercept to treat transfusion-dependent anemia due to very low, low, or intermediate risk myelodysplastic syndromes Recruiting
  2024-516009-22-00 5 2025-04-30 myelodysplastic neoplasms/syndromes (MDS)
• Study of MK-5684-based Therapies in Advanced Prostate Cancer Recruiting
  2023-506288-33-00 9 2025-03-03 Metastatic castration resistant prostate cancer (mCRPC)
• Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting
  2023-509632-26-00 9 2025-02-11 Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an
• Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting
  2024-513009-30-00 4 2024-11-21 Moderate to Severe Crohn’s Disease

Showing 25–48 of 139 trials